newsfilter
← Latest News
PR Newswire·

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-toleratedResults indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued